Skip to main content
Powered by ShareScore

Find research datasets worth reusing

Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.

3,514

datasets available to search

ShareScore release 0.9.0

Reset

Dataset results

3,514 results for “cell therapy”

Learn how ShareScore rates datasets ↗
ClinicalTrials.gov32/100

Stem Cell Educator Therapy in Diabetes

ClinicalTrials.gov study NCT03390231. IPD Sharing: UNDECIDED. Countries: 1. Publications: 4.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Intermittent Therapy in Metastatic Renal Cell Carcinoma Patients Treated With Ipilimumab and Nivolumab

ClinicalTrials.gov study NCT03126331. IPD Sharing: Not stated. Countries: 1. Publications: 2.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Immune Response on Neoadjuvant Therapy in Non-small-cell Lung Cancer (NSCLC)

ClinicalTrials.gov study NCT00406302. IPD Sharing: Not stated. Countries: 1. Publications: 1.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov32/100

Hematopoietic Stem Cell Transplantation Gene Therapy for Treatment of Severe Hemophilia A

ClinicalTrials.gov study NCT05265767. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov32/100

Humanized CAR-T Therapy for Treatment of B Cell Malignancy

ClinicalTrials.gov study NCT02782351. IPD Sharing: YES. Countries: 1. Publications: 4.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov32/100

Natural Killer-cell Therapy for Acute Myeloid Leukemia

ClinicalTrials.gov study NCT04347616. IPD Sharing: NO. Countries: 1. Publications: 1.

closedIPD-NOFeb 2026View details →
dryad32/100

High-throughput screen to identify and optimize NOT gate receptors for cell therapy

Open the record for dataset details and reuse information.

publicJul 2024View details →
dryad32/100

Adiponectin stimulates exosome release to enhance mesenchymal stem cell driven therapy of heart failure in mice

Open the record for dataset details and reuse information.

publicSep 2020View details →
zenodo28/100

SARS-CoV-2 infected host cell proteomics reveal potential therapy targets

<p>Determination of&nbsp;the SARS-CoV-2 infection profile by translatome and proteome proteomics at different times after infection; identification of&nbsp;drugs inhibiting viral replication.</p>

opencc-by-4.0Mar 2020View details →
dryad28/100

Data from: Cell therapy for chronic TBI: interim analysis of the randomized, controlled, double-blind STEMTRA trial

<p><b>Objective:</b> To determine if chronic motor deficits secondary to traumatic brain injury (TBI) can be improved by implantation of allogeneic modified bone marrow-derived mesenchymal stromal/stem cells (SB623).</p> <p><b>Methods:</b> This 6-month interim analysis of the 1-year double-blind, randomized, surgical sham-controlled, Phase 2 STEMTRA trial (NCT02416492) evaluated safety and efficacy of the stereotactic intracranial implantation of SB623 in patients with stable chronic motor deficits secondary to TBI. Patients in this multi-center trial (N=63) underwent randomization in a 1:1:1:1 ratio to 2.5x10<sup>6</sup>, 5.0x10<sup>6</sup>, 10x10<sup>6</sup> SB623 cells or control. Safety was assessed in patients who underwent surgery (N=61), and efficacy in the modified intent-to-treat population of randomized patients who underwent surgery (N=61; SB623=46, control=15).</p> <p><b>Results:</b> The primary efficacy endpoint of significant improvement from baseline of Fugl-Meyer Motor Scale score at 6 months for SB623-treated patients was achieved. SB623-treated patients improved by (LS mean [SE]) +8.3 (1.4) versus +2.3 (2.5) for control at 6 months, the LS mean difference was 6.0 (95% CI: 0.3-11.8); P=0.040. Secondary efficacy endpoints improved from baseline, but were not statistically significant versus control at 6 months. There were no dose-limiting toxicities or deaths, and 100% of SB623-treated patients experienced treatment-emergent adverse events versus 93.3% of control patients (P=0.25).</p> <p><b>Conclusions:</b> SB623 cell implantation appeared to be safe and well tolerated, and patients implanted with SB623 experienced significant improvement from baseline motor status at 6 months compared to controls.</p> <p><b>Classification of Evidence:</b> This study provides Class I evidence that implantation of SB623 was well tolerated and associated with improvement in motor status.</p>

opencc-zeroOct 2021View details →
zenodo28/100

Raw - EBV-specific CD8 T lymphocytes and B cells during glatiramer acetate therapy in patients with MS

<p>Intracellular staining&nbsp;overnight</p>

opencc-by-4.0Jan 2021View details →
zenodo28/100

Dataset for "Label-free enrichment of human pluripotent stem cell-derived early retinal progenitor cells for cell-based regenerative therapies"

<p>The raw dataset for "Label-free enrichment of human pluripotent stem cell-derived early retinal progenitor cells for cell-based regenerative therapies"</p> <p><span>DOI:</span><a href="https://doi.org/10.1016/j.stemcr.2023.12.001">https://doi.org/10.1016/j.stemcr.2023.12.001</a></p>

openMay 2023View details →
zenodo28/100

Fig. 3 in Microstructural Impact of Ischemia and Bone Marrow-Derived Cell Therapy Revealed With Diffusion Tensor Magnetic Resonance Imaging Tractography of the Heart In Vivo

Fig. 3. Amblyomma variegatum female before engorgement

opennotspecifiedDec 2014View details →
zenodo28/100

CAR T-cell therapy

SciDraw upload

opencc-by-4.0Aug 2024View details →
zenodo28/100

Data repository for the article: Fluorescence lifetime imaging unravels the pathway of glioma cell death upon hypericin-induced photodynamic therapy.

Open the record for dataset details and reuse information.

opencc-by-4.0Sep 2024View details →
ClinicalTrials.gov28/100

Lung-MAP: Durvalumab as Second-Line Therapy in Treating Patients With Recurrent Stage IV Squamous Cell Lung Cancer and No Matching Biomarkers

ClinicalTrials.gov study NCT02766335. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

UARK 2013-05 A Study of Autologous Expanded Natural Killer Cell Therapy for Asymptomatic Multiple Myeloma

ClinicalTrials.gov study NCT01884688. IPD Sharing: Not stated. Countries: 1. Publications: 0.

restrictedIPD-UNDECIDEDFeb 2026View details →
ClinicalTrials.gov28/100

A Study to Identify Barriers to Cellular Therapies for People With Plasma Cell Disorders

ClinicalTrials.gov study NCT06126341. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →
ClinicalTrials.gov28/100

Low Level Laser Therapy for Radiation Induced Dermatitis in H & N Squamous Cell Carcinoma

ClinicalTrials.gov study NCT02384434. IPD Sharing: NO. Countries: 1. Publications: 0.

closedIPD-NOFeb 2026View details →
ClinicalTrials.gov28/100

Pembro Plus CAR T-cell Therapy in R/R in PMBCL

ClinicalTrials.gov study NCT05934448. IPD Sharing: YES. Countries: 1. Publications: 0.

controlledIPD-YESFeb 2026View details →

ScienceDex guides

Understand access before you commit

These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.

Compare curated datasets

Allen Brain Atlas

Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.

allen-brain-atlas
neuroscienceopenDocumentation, web resources, and API references are available online.
Last verified 2026-04-30Open record

Annotated Behaviour and Observability Dataset (ABODe)

ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.

abode-home-cage
behavioral-neuroscienceopenThe DataShare record exposes download links for annotations, documentation, license text, and the zipped per-snippet data directory.
Last verified 2026-04-30Open record

DANDI Archive for NWB datasets

DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.

dandi-nwb
electrophysiologyopenPublished Dandiset metadata and archive endpoints are available through the production DANDI API.
Last verified 2026-04-30Open record

International Brain Laboratory public data

The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.

ibl
behavioral-neuroscienceopenPublic sessions can be searched and loaded from the IBL public data server through ONE.
Last verified 2026-04-29Open record

OpenNeuro

OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.

openneuro
neuroscienceopenPublished datasets are available on demand over the internet.
Last verified 2026-04-29Open record